老年类风湿关节炎患者长期低剂量糖皮质激素三个月内减停可行且安全:GLORIA试验后的安慰剂对照双盲减量研究
GLORIA试验中65岁以上类风湿关节炎患者接受泼尼松5 mg/日或安慰剂治疗2年后,按方案在3个月内线性减停盲法研究药物。减停后泼尼松组DAS28平均升高0.2,安慰剂组升高0.0,组间差异0.16(95%置信限-0.06,p=0.12);复发率泼尼松组45% vs 安慰剂组33%,RR 1.37(95%CI 0.95至1.98;p=0.12);未发现肾上腺功能不全证据。作者认为2年给药后减停低剂量泼尼松可行且安全。
要点
- 减停后泼尼松组DAS28平均升高0.2,安慰剂组升高0.0,组间差异0.16(95%置信限-0.06,p=0.12)。
- 复发率泼尼松组45% vs 安慰剂组33%,RR 1.37(95%CI 0.95至1.98;p=0.12)。
- 未发现肾上腺功能不全证据,作者认为2年给药后减停低剂量泼尼松可行且安全。
核心结论
- 减停泼尼松使疾病活动度中度升高至安慰剂组水平(均值仍处于低疾病活动度水平),并数值上增加复发风险,但无肾上腺功能不全证据。
- 作者认为2年给药后减停低剂量泼尼松可行且安全。
研究设计与样本
- GLORIA试验为随机安慰剂对照试验,评估泼尼松5 mg/日加标准治疗2年对65岁以上类风湿关节炎患者的获益与危害。
- 按方案,成功完成2年试验期的患者在3个月内线性减停盲法研究药物。
- 比较减停后治疗组间疾病活动度变化(单侧检验),次要结局(双侧检验)包括疾病复发和肾上腺功能不全症状/体征。
- 在来自3个荷兰中心的患者子集中,减停后检测 spot 血清样本中的皮质醇和ACTH。
主要发现
- 191例患者符合条件;36例符合治疗相关复发标准,仅纳入复发分析。
- 随访时DAS28平均(SD)变化:泼尼松组(n=76)0.2(1.0) vs 安慰剂组(n=79)0.0(1.2)。
- 经基线校正,组间DAS28升高差异为0.16(95%置信限-0.06,p=0.12)。
- 复发发生于泼尼松组45% vs 安慰剂组33%,相对风险(RR)1.37(95%CI 0.95至1.98;p=0.12)。
- 未发现肾上腺功能不全证据。
关键数值与推荐
- 复发定义为减停第4周后DAS28增加>0.6、开放标签糖皮质激素使用或改善病情抗风湿药(DMARD)增加/更换。
- 减停方案为按方案在3个月内线性减停盲法研究药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The randomised placebo-controlled GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial evaluated the benefits and harms of prednisolone 5 mg/day added to standard care for 2 years in patients aged 65+ years with rheumatoid arthritis (RA). Here, we studied disease activity, flares and possible adrenal insufficiency after blinded withdrawal of study medication. METHODS: Per protocol, patients successfully completing the 2-year trial period linearly tapered and stopped blinded study medication in 3 months. We compared changes in disease activity after taper between treatment groups (one-sided testing). Secondary outcomes (two-sided tests) comprised disease flares (DAS28 (Disease Activity Score 28 joints) increase >0.6, open-label glucocorticoids or disease-modifying antirheumatic drug (DMARD) increase/switch after week 4 of tapering) and symptoms/signs of adrenal insufficiency. In a subset of patients from 3 Dutch centres, cortisol and ACTH were measured in spot serum samples after tapering. RESULTS: 191 patients were eligible; 36 met treatment-related flare criteria and were only included in the flare analysis. Mean (SD) DAS28 change at follow-up: 0.2 (1.0) in the prednisolone group (n=76) vs 0.0 (1.2) in placebo (n=79). Adjusted for baseline, the between-group difference in DAS28 increase was 0.16 (95% confidence limit -0.06, p=0.12). Flares occurred in 45% of prednisolone patients compared with 33% in placebo, relative risk (RR) 1.37 (95% CI 0.95 to 1.98; p=0.12). We found no evidence for adrenal insufficiency. CONCLUSIONS: Tapering prednisolone moderately increases disease activity to the levels of the placebo group (mean still at low disease activity levels) and numerically increases the risk of flare without evidence for adrenal insufficiency. This suggests that withdrawal of low-dose prednisolone is feasible and safe after 2 years of administration.
引用
- Almayali AAH, Boers M, Hartman L, et al. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. Ann Rheum Dis. 2023. PMID: 37541762. doi:10.1136/ard-2023-223977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。